Effects of renal denervation on monocrotaline induced pulmonary remodeling
Metrics: PDF 678 views | HTML 1899 views | ?
Qian Liu1,*, Jiyang Song2, Dasheng Lu1,*, Jie Geng1, Zhixin Jiang1, Kai Wang1, Bin Zhang1 and Qijun Shan1
1Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
2Department of Cardiology, Gansu Provincial Hospital, Lanzhou, China
*These authors contributed equally to this work
Qijun Shan, email: email@example.com
Keywords: renal denervation, monocrotaline, pulmonary remodeling
Received: November 04, 2016 Accepted: January 24, 2017 Published: February 07, 2017
Pulmonary artery hypertension (PAH) is a rapidly progressive disorder, which leads to right heart failure and even death. Overactivity of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system accounts for the development and progression of PAH. The role of renal denervation (RDN) in different periods of PAH has not been fully elucidated. A single intraperitoneal injection of monocrotaline (MCT, 60 mg/kg) was used to induce pulmonary remodeling in male Sprague Dawley rats (n = 40). After 24-hour of MCT administration, a subset of rats underwent RDN (RDN24h, n = 10); after 2-week of MCT injection, another ten rats received RDN treatment (RDN2w, n = 10) and the left 20 rats were divided to MCT group with sham RDN operation (MCT, n = 20). Eight rats in Control group received intraperitoneal injection of normal saline (60 mg/kg) once and sham RDN surgery. After 35 days, tissue and blood samples were collected. Histological analysis demonstrated that the collagen volume fraction of right ventricle, lung tissue and pulmonary vessel reduced significantly in RDN24h group but not in the RDN2w group, compared with MCT group. Moreover, the earlier RDN treatment significantly decreased SNS activity and blunted RAAS activation. Importantly, RDN treatment significantly improved the survival rate. In summary, earlier RDN treatment could attenuate cardio-pulmonary fibrosis and therefore might be a promising approach to prevent the development of PAH.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.